Gemcitabine Plus Cisplatin in Treating Patients With Metastatic Kidney Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 31, 1999

Primary Completion Date

February 28, 2005

Study Completion Date

April 30, 2006

Conditions
Kidney Cancer
Interventions
DRUG

cisplatin

Cisplatin IV over 60 minutes on day 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

DRUG

gemcitabine hydrochloride

Gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Trial Locations (1)

44106-5065

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT00003928 - Gemcitabine Plus Cisplatin in Treating Patients With Metastatic Kidney Cancer | Biotech Hunter | Biotech Hunter